<DOC>
	<DOCNO>NCT03007524</DOCNO>
	<brief_summary>This prospective , randomized trial compare different dos rosuvastatin patient acute coronary syndrome post drug-eluting stent implantation . Through study , investigator aim evaluate effect high dose rosuvastatin calcium `` target vessel '' endothelialization `` non-target vessel '' plaque stability . Moreover , investigator may provide mechanically evidence clinical application high dose rosuvastatin patient acute coronary syndrome .</brief_summary>
	<brief_title>Early Vascular Healing Acute Coronary Syndrome Patients With Different Doses Rosuvastatin</brief_title>
	<detailed_description>This prospective , multicenter , randomize control clinical trial compare different dos rosuvastatin patient acute coronary syndrome post drug-eluting stent implantation . In total , investigator plan recruit 80 patient acute coronary syndrome ( acute ST-segment elevation myocardial infarction ) participate study . After sign informed consent form , patient randomly assign high dose rosuvastatin low dose rosuvastatin group ( 40 case group ) computer generate random sequence table ratio 1:1 . Patients high-dose group prescribe rosuvastatin calcium 20mg/d least 6 month post index procedure , patient low dose group rosuvastatin calcium 10mg/d , also least 6 month . Additionally , patient receive dual antiplatelet therapy ( oral aspirin 100mg qd , clopidogrel 75mg qd ticagrelor 90 mg bid ) . Clinical follow ( telephone out-patient follow-up ) schedule 30 day , 6 month , 1 year , 2 year 3 year . Optical coherence tomography examination perform 6 month . Neointimal hyperplasia , stent strut coverage thin cap fibroatheroma primary observational parameter . Multi-slices CT optional pre-/post-procedure 3 year follow-up . All clinical data collect managed statistical center , clinical endpoint adjudication committee . All image modality data collect analysed independent image core laboratory .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . 18 75 year male nonpregnant female ; 2 . Clinical evidence unstable angina non ST segment elevation myocardial infarction ( NSTEMI ) ; 3 . The patient two de novo native coronary lesion different epicardial vessel ; 4 . Target lesion diameter stenosis ≧70 % ( visually estimate ) ; 5 . Each target lesion must treat maximal 2 stent ( except bailout stenting ) ; 6 . Low density lipoprotein ( LDL ) high 100mg/dL low 100mg/dL take statin drug less 1 month enrol ; 7 . Patient acceptable candidate emergency coronary artery bypass grafting ; 8 . The patient able understand aim study , provide voluntarily write inform content agree followup visit include angiographic、multislice spiral compute tomography ( MSCT ) optical coherence tomography ( OCT ) examination ; 1 . Any acute myocardial infarction within past 1 month ; myocardial enzyme back normal myocardial infarction ; 2 . Chronic total occlusive lesion , severe leave main coronary artery disease , orifice lesion , 3vessel disease , bifurcation lesion ( side branch diameter great 2 mm , orifice diameter stenosis great equal 50 % , side branch need protect guidewire balloon ) , OCT image suitable lesion site OCT image incomplete , Target lesion locate previous venous arterial bypass graft , Target lesion visible thrombus , intercurrent infection , inflammatory disease . ; 3 . Heavily calcified lesion , severely tortuous lesion , lesion well predilated and/or unsuitable stent crossover/expansion ; 4 . Instent restenosis lesion ; 5 . Prior percutaneous coronary intervention ( PCI ) within past 1 year ; plan possibly reintervention within 1 year post indexprocedure ; previous PCI 1 year target vessel ; 6 . Instability hemodynamic respiratory cycle , cardiogenic shock , Heart failure severe symptom ( New York Heart Association III ( NYHA III ) ) leave ventricular ejection fraction le 40 % ( UCG leave ventricle radiography ) ; 7 . Known renal insufficiency ( e.g , Glomerular filtration rate ( eGFR ) &lt; 60 ml/kg/m2 serum creatinine level &gt; 2.5 mg/dL , subject dialysis ) ; 8 . History bleeding tendency , active peptic ulcer cerebral hemorrhage retinal hemorrhage , half year history stroke , antiplatelet agent anticoagulant therapy contraindication anticoagulation patient ; 9 . Patients use statin lipidlowering drug treatment 1 month enrol , patient allergy rosuvastatin use rosuvastatin contraindication , patient allergy aspirin , clopidogrel ticagrelor , heparin , contrast agent , polymer , zotarolimus metal ; 10 . Life expectancy &lt; 6 month ; 11 . Currently participate investigational drug another device study complete primary endpoint ; 12 . Unable unwilling comply protocol expect complete study period , include followup requirement ; 13 . The patient recipient heart transplant ; 14 . Unstable arrhythmia , high risk ventricular contraction , ventricular arrhythmia ; 15 . With need chemotherapy 30 day due malignancy ; 16 . Patients immune suppression autoimmune disease plan currently receive immunosuppressive therapy ; 17 . Patients plan currently receive longterm anticoagulation therapy ; 18 . Patients may receive surgery within 6 month post indexprocedure need stop aspirin , clopidogrel ticagrelor ; 19 . Neutropenia ( &lt; 1000 neutrophils/mm3 ) , Thrombocytopenia ( &lt; 100,000 platelets/mm3 ) , Confirmed suspect diagnosis liver diseases ; 20 . Patients diffuse peripheral vascular disease preclude 6 French unit ( 6F ) sheath insertion ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>rosuvastatin</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>acute coronary syndrome</keyword>
</DOC>